Is Oncotype DX testing informative for breast cancers with low ER expression? A retrospective review from a biomarker testing referral center

Is Oncotype DX testing informative for breast cancers with low ER expression? A retrospective review from a biomarker testing referral center

Purpose: It remains unclear whether patients with HER2-negative, low-estrogen receptor (ER-low)-positive early breast cancer (BC) benefit from Oncotype DX® (ODX) testing. Methods: We conducted a retrospective review of cases referred for ODX testing over a seven-year period from a breast biomarker t...

Full description

Bibliographic Details
Main Authors: John Loggie, Penelope J. Barnes, Michael D. Carter, Daniel Rayson, Gillian C. Bethune
Format: Article
Language:English
Published: Elsevier 2024-06-01
Series:Breast
Subjects:
ER-low
Breast cancer
Estrogen receptor
Oncotype DX
Expression intensity
Immunohistochemistry
Online Access:http://www.sciencedirect.com/science/article/pii/S0960977624000468

Internet

http://www.sciencedirect.com/science/article/pii/S0960977624000468

Similar Items